Reining in statin scripts

Last year, the US Food and Drug Administration announced labels for statins must include the warning of a slight increased risk of type 2 diabetes mellitus.

In some quarters the move raised eyebrows; in others it raised blood pressure, amid fears patients would abandon the treatment in droves.

Academia, represented by researchers such as Professor Tony Keech, deputy director of the NHMRC Clinical Trials Centre in Sydney, is adamant about the role of statins.